Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
Reid W. Merryman(Harvard University), Heather A. Jacene(Brigham and Women's Hospital), Eleanor Taranto(Unknown), Robert Redd(Harvard University), Heiko Schöder(Memorial Sloan Kettering Cancer Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Hyesun Park(Brigham and Women's Hospital), Gulrayz Ahmed(Medical College of Wisconsin), Caron A. Jacobson(Dana-Farber Cancer Institute), Patrizia Mondello(WinnMed), Erin M. Parry(Broad Institute), Erin Jeter(Dana-Farber Cancer Institute), Laure Michaud(Memorial Sloan Kettering Cancer Center), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Matthew Chase(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Matthew Robertson(Brigham and Women's Hospital), Gabriela Spilberg(Brigham and Women's Hospital)
Cited by 11
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k